Literature DB >> 1268491

Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

L F Prescott, K K Adjepon-Yamoah, R G Talbot.   

Abstract

Plasma concentrations of lignocaine were measured during and after infusion of lignocaine at 1.4 mg/min for 36-46 hours in 12 patients with myocardial infarction and one patient with cardiac failure due to uncontrolled ventricular tachycardia. In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4.3 hours compared with 1.4 hours in healthy subjects. Mean plasma lignocaine concentrations were significantly higher in seven patients with cardiac failure, and concentrations also rose during the infusion and the half life was considerably prolonged to 10.2 hours. Lignocaine concentrations rose rapidly to toxic levels when cardiogenic shock developed in one patient and did not fall when the infusion was stopped. The mean plasma antipyrine half life was moderately prolonged (19.4 hours) in a larger group of patients with myocardial infarction and cardiac failure but returned to normal during convalescence (13.2 hours). The metabolism of lignocaine is grossly abnormal in patients with cardiac failure and cardiogenic shock after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1268491      PMCID: PMC1639291          DOI: 10.1136/bmj.1.6015.939

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  13 in total

1.  Blood levels of lidocaine after various infusion rates in patients with acute myocardial infarction.

Authors:  L Rydén; A Waldenström; Y Winsnes; B Ortengren
Journal:  Am Heart J       Date:  1975-04       Impact factor: 4.749

2.  Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite.

Authors:  H Halkin; P Meffin; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

3.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Authors:  R G Talbot; J Nimmo; D G Julian; R A Clark; J M Neilson; L F Prescott
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

4.  Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

Authors:  W Sadée; R Schröder; E von Leitner; M Dagcioglu
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

5.  Identification of glycinexylidide in patients treated with intravenous lidocaine.

Authors:  J M Strong; M Parker; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1973 Jan-Feb       Impact factor: 6.875

6.  Pharmacokinetics of lidocaine in man.

Authors:  R N Boyes; D B Scott; P J Jebson; M J Godman; D G Julian
Journal:  Clin Pharmacol Ther       Date:  1971 Jan-Feb       Impact factor: 6.875

7.  Rapid gas-liquid chromatographic estimation of antipyrine in plasma.

Authors:  L F Prescott; K K Adjepon-Yamoah; E Roberts
Journal:  J Pharm Pharmacol       Date:  1973-03       Impact factor: 3.765

8.  Gas-liquid chromatographic estimation of lignocaine, ethylglycylxylidide, glycylxylidide and 4-hydroxyxylidine in plasma and urine.

Authors:  K K Adjepon-Yamoah; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1974-11       Impact factor: 3.765

9.  Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide.

Authors:  J M Strong; D E Mayfield; A J Atkinson; B C Burris; F Raymon; L T Webster
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

10.  Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure.

Authors:  O Tokola; O Pelkonen; N T Karki; P Luoma
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

View more
  32 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Lignocaine kinetics in cardiac patients and aged subjects.

Authors:  R L Nation; E J Triggs; M Selig
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 5.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

6.  The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.

Authors:  A H Thomson; H L Elliott; A W Kelman; P A Meredith; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

7.  Reappraisal of lignocaine therapy in management of myocardial infarction.

Authors:  B L Pentecost; J V De Giovanni; P Lamb; P J Cadigan; K L Evemy; E J Flint
Journal:  Br Heart J       Date:  1981-01

8.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

Review 10.  Pharmacokinetics in patients with cardiac failure.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.